Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody

References

• Amano J, Masuyama N, Hirota Y, et al. (2010). Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. Drug Metab Dispos 38:2339–46
   Google Scholar
• Andersen JT, Daba MB, Berntzen G, et al. (2010). Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 285:4826–36
   PubMed Web of Science ®Google Scholar
• Bauer RJ, Dedrick RL, White ML, et al. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420
   PubMedGoogle Scholar
• Belldegrin A, Shoenfeld Y, Pick AI, Vana D. (1980). Age related distribution of serum immunoglobulin concentration in 1003 healthy children and adults. Biomedicine 33:8–12
   PubMedGoogle Scholar
• Bernett MJ, Chu SY, Leung I, et al. (2013). Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. MAbs 5:384–96
   PubMed Web of Science ®Google Scholar
• Betts AM, Clark TH, Yang J, et al. (2010). The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13
   PubMed Web of Science ®Google Scholar
• Black RS, Sperling RA, Safirstein B, et al. (2010). A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24:198–203
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Wong A, Drake E, et al. (2011). Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 3:376–86
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Rugo HS, Vukelja SJ, et al. (2011). Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–16
   PubMed Web of Science ®Google Scholar
• Cosson VF, Ng VW, Lehle M, Lum BL. (2014). Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73:737–47
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, et al. (2007). Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 35:86–94
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, et al. (2011). Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 3:61–6
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, et al. (2010). Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600–5
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Tahara M, et al. (2009). Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol 14:307–14
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, et al. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131–42
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim JK, et al. (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690–6
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Sutjandra L, Doshi S, et al. (2012). Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51:247–60
   PubMedGoogle Scholar
• Glaesner W, Vick AM, Millican R, et al. (2010). Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26:287–96
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Cooper KD, McCormick TS, et al. (2007). A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 23:1081–92
   PubMed Web of Science ®Google Scholar
• Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. (2007). A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63:548–61
   PubMed Web of Science ®Google Scholar
• Herbst RS, Johnson DH, Mininberg E, et al. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544–55
   PubMed Web of Science ®Google Scholar
• Hernandez-Bernal F, Garcia-Garcia I, Gonzalez-Delgado CA, et al. (2005). Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos 26:151–9
   PubMedGoogle Scholar
• Igawa T, Ishii S, Tachibana T, et al. (2010a). Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203–7
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, et al. (2010b). Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385–92
   PubMed Web of Science ®Google Scholar
• Israel EJ, Taylor S, Wu Z, et al. (1997). Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92:69–74
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, et al. (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89:573–8
   PubMed Web of Science ®Google Scholar
• Jones EA, Waldmann TA. (1972). The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51:2916–27
   PubMed Web of Science ®Google Scholar
• Junghans RP, Anderson CL. (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512–16
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. (2009). Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137:1628–40
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. (2012). A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18:1570–4
   PubMed Web of Science ®Google Scholar
• Kloft C, Graefe EU, Tanswell P, et al. (2004). Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs 22:39–52
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. (2007). Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 46:645–60
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Rubin AS, Hanna RK, et al. (2000). The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 34:161–4
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Hasunuma T, Padhi D. (2011). A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 49:1101–7
   PubMed Web of Science ®Google Scholar
• Lee JH, Cho JH, Yeo J, et al. (2013). The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein. Biologicals 41:77–83
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, et al. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371–8
   PubMed Web of Science ®Google Scholar
• Ling J, Zhou H, Jiao Q, Davis HM. (2009). Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49:1382–402
   PubMed Web of Science ®Google Scholar
• Lopez EL, Contrini MM, Glatstein E, et al. (2010). Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 54:239–43
   PubMed Web of Science ®Google Scholar
• Luu KT, Bergqvist S, Chen E, et al. (2012). A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341:702–8
   PubMed Web of Science ®Google Scholar
• Ma P, Yang BB, Wang YM, et al. (2009a). Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 49:1142–56
   PubMed Web of Science ®Google Scholar
• Ma Y, Lin BR, Lin B, et al. (2009b). Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 30:364–71
   PubMed Web of Science ®Google Scholar
• Marathe A, Peterson MC, Mager DE. (2008). Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 326:555–62
   PubMed Web of Science ®Google Scholar
• Martin WL, West AP Jr, Gan L, Bjorkman PJ. (2001). Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7:867–77
   PubMed Web of Science ®Google Scholar
• McMahon FG, Vargas R, Ryan M, et al. (1990). Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76:1718–22
   PubMed Web of Science ®Google Scholar
• Morell A, Terry WD, Waldmann TA. (1970). Metabolic properties of IgG subclasses in man. J Clin Invest 49:673–80
   PubMed Web of Science ®Google Scholar
• Mori K, Iida S, Yamane-Ohnuki N, et al. (2007). Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology 55:109–14
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J, et al. (2007). Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 64:278–91
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea, E, Reichert JM. (2010). Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–74
   PubMed Web of Science ®Google Scholar
• Ng CM, Stefanich E, Anand BS, et al. (2006). Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23:95–103
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, et al. (2003). Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 30:1426–35
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie, V, Ward ES. (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551–9
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, et al. (2006). Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759–69
   PubMed Web of Science ®Google Scholar
• PMDA. (2001). Herceptin: information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P200100003/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2002). Synagis: information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P200200010/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2005). Actemra: information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P200500016/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2009). Xolair: information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P200900001/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2011a). Simponi: Information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P201100114/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2011b). Stelera: Information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P201100021/index.html [last accessed 12 Feb 2014]
   Google Scholar
• PMDA. (2012). Ranmark: Information on new drug approval. Available from: http://www.info.pmda.go.jp/shinyaku/P201200013/index.html [last accessed 12 Feb 2014]
   Google Scholar
• Reichert JM. (2012). Marketed therapeutic antibodies compendium. MAbs 4:413–15
   PubMed Web of Science ®Google Scholar
• Richter WF, Bhansali SG, Morris ME. (2012). Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559–70
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'Acqua WF, et al. (2013). A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147–53
   PubMed Web of Science ®Google Scholar
• Rodewald R. (1973). Intestinal transport of antibodies in the newborn rat. J Cell Biol 58:189–211
   PubMed Web of Science ®Google Scholar
• Rojas JR, Taylor RP, Cunningham MR, et al. (2005). Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578–85
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. (2010). Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 602:93–104
   PubMedGoogle Scholar
• Saez-Llorens X, Moreno MT, Ramilo O, et al. (2004). Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 23:707–12
   PubMed Web of Science ®Google Scholar
• Stein C, Kling L, Proetzel G, et al. (2012). Clinical chemistry of human FcRn transgenic mice. Mamm Genome 23:259–69
   Google Scholar
• Stephenson JJ, Gregory C, Burris H, et al. (2009). An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer 8:29–37
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, et al. (2010). Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184:1968–76
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, et al. (2013). Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 5:397–405
   PubMed Web of Science ®Google Scholar
• Tanaka T, Seino Y, Fujieda K, et al. (1999). Pharmacokinetics and metabolic effects of high-dose growth hormone administration in healthy adult men. Endocr J 46:605–12
   PubMedGoogle Scholar
• Tobinai K, Kobayashi Y, Narabayashi M, et al. (1998). Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 9:527–34
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Watanabe T, Omuro Y, et al. (1999). Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81:1419–25
   PubMed Web of Science ®Google Scholar
• Vaidyanathan A, McKeever K, Anand B, et al. (2011). Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci 119:116–25
   PubMed Web of Science ®Google Scholar
• Vaughn DE, Bjorkman PJ. (1998). Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 6:63–73
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Szklut P, Wensel D, et al. (2011). Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 28:1696–706
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Strober W. (1969). Metabolism of immunoglobulins. Prog Allergy 13:1–110
   PubMedGoogle Scholar
• Weiner LM, Surana, R, Wang S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–27
   PubMed Web of Science ®Google Scholar
• West AP Jr, Bjorkman PJ. (2000). Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39:9698–708
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, et al. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:7663–71
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, et al. (2012). Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4:475–87
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, et al. (2007). Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47:383–96
   PubMed Web of Science ®Google Scholar